Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes

被引：12

作者：

Braun, Juergen ^{[1
]}

Kiltz, Uta ^{[1
]}

Sarholz, Michael ^{[1
]}

Heldmann, Frank ^{[1
]}

Regel, Andrea ^{[1
]}

Baraliakos, Xenofon ^{[1
]}

机构：

[1] Rheumazentrum Ruhrgebiet, D-44649 Herne, Germany

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2015年 / 11卷 / 08期

关键词：

ankylosing spondylitis; disease activity; imaging; mobility; monitoring; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SOCIETY CLASSIFICATION CRITERIA; DISEASE-ACTIVITY SCORE; RESONANCE-IMAGING EXAMINATIONS; EVIDENCE-BASED RECOMMENDATIONS; DIFFERENT TREATMENT RESPONSES; ALPHA-ANTAGONIST THERAPY; ANTI-TNF THERAPY; SPINAL MOBILITY; DOUBLE-BLIND;

D O I：

10.1586/1744666X.2015.1052795

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Patient assessment in axial spondyloarthritis (axSpA) is multidimensional, and monitoring of disease activity, function and radiographic progression is complex. There is no simple 'gold standard' for measuring disease activity in all individual patients, as disease activity in axSpA is the sum of many different aspects and a complexity that cannot be represented by a single variable. Limited spinal mobility is a cardinal sign of ankylosing spondylitis and loss of spinal mobility has been reported to be a prognostic factor and most often evaluated with the Bath Ankylosing Spondylitis Functional Index. Imaging of the spine and assessment of safety aspects plays an important role in the monitoring of patients with axSpA. The timeframe for collecting information regarding disease activity, function and radiographic progression are recommended on an individual basis.

引用

页码：935 / 946

页数：12

共 114 条

[1]

Anderson JJ, 2001, ARTHRITIS RHEUM-US, V44, P1876, DOI 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO

[2]

2-F

[3] Serum MMP-3 Level as a Biomarker for Monitoring and Predicting Response to Etanercept Treatment in Ankylosing Spondylitis [J].